Cases & Deals

  • Home
  • Practices
  • Cougar Biotech gets purchased by J & J, including global patent portfolio for prostate cancer treatment

Share

Cougar Biotech gets purchased by J & J, including global patent portfolio for prostate cancer treatment

June 2008

Client(s) Cougar Biotechnology, Inc.

Jones Day assisted Cougar Biotechnology in the management and prosecution of a worldwide patent portfolio for the phase III clinical candidate, abiraterone acetate, which is being developed for use in the treatment of prostate cancer and which resulted in the sale of Cougar to Johnson & Johnson for $970 million.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.